Highlights Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 03:30:00 26/06/2024 am IST			5-day change	1st Jan Change
19.68 ^CAD	-0.25%		-0.05%	-6.95%

12:39pm	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
24/06	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	04:09pm	RE
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06	RE
J&J: 50M pupils helped through 'Sight for Kids' program	24/06	CF
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06	MT
Johnson & Johnson: acquisition of Proteologix completed	21/06	CF
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	21/06	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	21/06	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	21/06	CI
J&J: launches open, secure digital ecosystem	20/06	CF
J&J: promising results in Crohn's disease	20/06	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	20/06	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	20/06	DJ
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease	20/06	CI
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	17/06	CI
J&J: positive results in Sjögren's disease	17/06	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	17/06	MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	15/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST